Omeros Corp (OMER) Gets a Buy Rating from H.C. Wainwright

By Ryan Adsit

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Omeros Corp (OMERResearch Report) today and set a price target of $35.00. The company’s shares closed last Monday at $17.15.

According to TipRanks.com, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -17.2% and a 27.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and Turning Point Therapeutics Inc.

Currently, the analyst consensus on Omeros Corp is a Moderate Buy with an average price target of $28.33.

See today’s analyst top recommended stocks >>

The company has a one-year high of $20.92 and a one-year low of $10.30. Currently, Omeros Corp has an average volume of 411.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.